MyDosage · Personal evidence dossier

Injury recovery

Soft-tissue and joint repair candidates — mostly preclinical mechanism.

DSR-RECO-20260820

Issued August 20, 2026

Editorial · independent

01Top candidate

Thymosin β4 (full)

Actin-sequestering peptide · t½ ~2 h

Full-length 43-aa Tβ4. Distinct from the TB-500 fragment; clinical trials in dry-eye and cardiac repair.

Evidence Intelligence Score™

5.3/ 10Emerging

Strongest

Early human signals exist, primarily from observational and pilot work — directional, not definitive.

Weakest

Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.

Unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Outlook

Outlook: directional. The next 12–24 months of registered trials will determine whether the early signal holds.

02Ranked candidates

03Safety register